RANKL-Specific Agent for Metastatic Lesion Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments fail to effectively prevent or reduce premetastatic lesions and metastasis formation, as they do not adequately address the role of platelet-expressed RANKL in promoting metastasis through RANK-RANKL signaling.
Innovation Solution
A RANKL-specific antagonistic agent that recognizes and neutralizes human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL) to inhibit metastasis by preventing the formation of premetastatic circulating cell aggregates and reducing RANK-RANKL signaling, thereby inhibiting the transformation of cancer cells into prometastatic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments are used, then general tumor targeting is achieved, but premetastatic lesions and metastasis formation are not effectively prevented
Solution Approach 1:
The patent applies local quality by developing an agent that specifically targets platelet-expressed RANKL (pRANKL) rather than RANKL in general. The agent has differential binding characteristics: it binds with high affinity to pRANKL on activated platelets while showing reduced binding to RANKL on osteoblasts and bone tissue. This localized specificity allows the treatment to prevent metastasis without causing widespread bone loss or osteoporosis, thereby improving reliability in preventing metastasis while maintaining adaptability to different tissue contexts.
2Object-affected harmful factors
If RANKL is broadly inhibited to prevent bone metastasis, then osteoclast activity is reduced, but bone destruction protection is achieved at the cost of affecting normal bone remodeling
Solution Approach 1:
The agent exhibits local quality through tissue-specific binding preferences. It preferentially binds to pRANKL on activated platelets involved in metastatic processes while having lower affinity for RANKL on osteoblasts and bone tissue. This selective binding pattern allows the agent to protect against bone destruction caused by metastatic osteoclast activation without significantly interfering with normal physiological bone remodeling processes, thus reducing harmful side effects on healthy bone tissue.
Solution Approach 2:
The patent introduces platelets as an intermediary target. Rather than directly inhibiting RANKL-bone interaction, the agent targets pRANKL expressed on activated platelets that facilitate metastatic spread. Platelets act as carriers or mediators that deliver RANKL to metastatic sites, and by blocking this platelet-associated RANKL, the agent prevents metastatic bone destruction while leaving normal bone remodeling pathways relatively intact.
3Object-generated harmful factors
If platelet-tumor cell aggregates are formed to promote metastasis, then tumor cell protection from immune elimination is achieved, but metastatic progression is enhanced
Solution Approach 1:
The patent applies the 'blessing in disguise' principle by targeting the very mechanism that protects tumor cells. Platelet-tumor cell aggregates normally protect tumor cells from immune elimination, but this same aggregation process involves pRANKL expression that promotes metastasis. The agent binds to pRANKL on these aggregates, converting the protective function into a therapeutic target. By disrupting the RANKL signaling in these aggregates, the agent simultaneously compromises their protective function and prevents their metastatic function, turning a harmful protective mechanism into a vulnerability that can be exploited therapeutically.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent effectively reduces the dissemination of premetastatic tumor cells, inhibits platelet and cancer cell activation, and decreases the risk of metastasis formation by downmodulating premetastatic lesions, thereby improving treatment outcomes for cancer patients.
Implementation Method 1
a RANKL-specific antagonistic agent which recognizes and optionally neutralizes human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL)
Data Source
AI summary
The invention provides for a RANKL-specific antagonistic agent recognizing human platelet-expressed receptor activator of nuclear factor kappa-B ligand (pRANKL), for use in treating a cancer patient to prevent or reduce premetastatic lesions in blood.